TOPBP1 and ovarian cancer: However, Karakashev et al. demonstrated that combination treatment with BET inhibition suppressed TOPBP1 and WEE1 expression, resulting in accumulation of DNA damage, checkpoint defects, and apoptosis in preclinical models of BRCA-wild type ovarian cancer [15].